Provided by Tiger Trade Technology Pte. Ltd.

Recursion Pharmaceuticals, Inc.

4.63
-0.1500-3.14%
Pre-market: 4.50-0.1300-2.81%06:22 EDT
Volume:71.11M
Turnover:331.34M
Market Cap:2.48B
PE:-4.53
High:5.19
Open:4.81
Low:4.40
Close:4.78
52wk High:7.18
52wk Low:2.77
Shares:535.00M
Float Shares:522.33M
Volume Ratio:2.25
T/O Rate:13.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0219
EPS(LYR):-1.4410
ROE:-56.58%
ROA:-27.33%
PB:2.71
PE(LYR):-3.21

Loading ...

Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals today

TIPRANKS
·
Yesterday

NASD Most Active Issues

Dow Jones
·
Yesterday

Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)?

Simply Wall St.
·
Oct 03

One Weekend, Thousands Of Compounds: Inside Microsoft's New AI Biology Model

AI Industry Frontlines
·
Oct 03

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

From Exoskeletons to AI: ChronoScale's Billion-Dollar Pivot

Tech News Roundup
·
Oct 02

Recursion Licenses TxFM RNA Foundation Model to Tempus AI for Oncology Use in USD 12 Million Deal

Reuters
·
Sep 22

Tempus Extends Data Licensing Partnership with Recursion Through November 2029

Reuters
·
Sep 22

Tempus AI, Recursion Extend Data License, Amend Fee Structure

MT Newswires Live
·
Sep 21

Recursion, Tempus Expand AI and RNA Collaboration Agreements

TIPRANKS
·
Sep 21

Tempus AI, Recursion extend data license agreement, enter new license agreement

TIPRANKS
·
Sep 21

Tempus AI, - Recursion Grants Tempus Non-Exclusive Worldwide License to Rna Sequencing Model Txfm

THOMSON REUTERS
·
Sep 21

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s Rna Foundation Model

THOMSON REUTERS
·
Sep 21

Tempus AI, -Co and Recursion Extend Data Partnership Through November 2029

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Enters Amendment to Master Agreement with Tempus on Sept 15, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Eliminates Co's Right to Terminate Agreement for Convenience - SEC Filing

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Extends Agreement Term from Five to Six Years - SEC Filing

THOMSON REUTERS
·
Sep 21

Recursion’s REC-7735 Trial: Early Precision Oncology Data That Could Move RXRX

TIPRANKS
·
Sep 18

Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (RXRX), Teladoc (TDOC) and Oscar Health (OSCR)

TIPRANKS
·
Sep 16

Recursion Pharma CEO Najat Khan Sells 22,408 Shares for $78,822

Reuters
·
Sep 11